Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03654976 · ClinicalTrials.gov registry record · Phase 3
Mite Asthma Pediatric Immunotherapy Trial
A Phase 3 study, sponsored by ALK-Abelló A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 533
- Enrollment target
NCT03654976 is a Phase 3 study that has completed, run by ALK-Abelló A/S. The registered enrollment target is 533 participants.
The verdict
NCT03654976, a Phase 3 study, has completed, sponsored by ALK-Abelló A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 533 participants
- Enrollment target
Study Summary
The trial aims to demonstrate efficacy of the House Dust Mite SLIT-tablet versus placebo as add-on treatment in children and adolescents (5-17 years) with House Dust Mite allergic asthma based on clinically relevant asthma worsening.
Interventions
- OTHER Placebo
- BIOLOGICAL HDM SLIT-tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 533 participants |
| Start Date | 2018-02-22 |
| Est. Completion | 2022-05-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03654976
The ClinicalTrials.gov registry entry for NCT03654976 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 533 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ALK-Abelló A/S, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03654976 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03654976 about?
NCT03654976 is a clinical study titled "Mite Asthma Pediatric Immunotherapy Trial". The trial aims to demonstrate efficacy of the House Dust Mite SLIT-tablet versus placebo as add-on treatment in children and adolescents (5-17 years) with House Dust Mite allergic asthma based on clinically relevant asthma worsening.
What is the current status of trial NCT03654976?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 533 participants. The study started on 2018-02-22. Estimated completion is 2022-05-31.
What interventions are being tested in trial NCT03654976?
The interventions under investigation include: Placebo (OTHER), HDM SLIT-tablet (BIOLOGICAL).
Who is sponsoring clinical trial NCT03654976?
This trial is sponsored by ALK-Abelló A/S, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.